ximelagatran


Also found in: Wikipedia.

ximelagatran

An oral direct thrombin inhibitor drug used as an anticoagulant alternative to warfarin in the management of thromboembolism. In late 2004 the American FDA rejected an application for approval of this drug on the grounds of liver toxicity.
References in periodicals archive ?
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
Stroke prevention with aspirin, warfarin, and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
2) This review included the 3 studies of dabigatran, rivaroxaban, and apixaban from the previously described review, as well as 2 trials of ximelagatran that were not included in the other review (presumably because ximelagatran was no longer available owing to liver toxicity).
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis.
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
8,13) However, a similar signal of increased cardiac events and MI was also observed with another DTI, ximelagatran.
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial.
Su eficacia clinica en la prevencion del accidente vascular cerebral embolico en pacientes con FA fue evaluado en los estudios SPORTIF III y V (2-4), en cuyos resultados hubo indicios de un mayor riesgo de infarto de miocardio en los pacientes que recibieron Ximelagatran en comparacion a los que recibieron warfarina o heparina de peso molecular bajo, asi como evidencia de toxicidad hepatica (2-5), lo cual provoco la salida del referido producto del mercado farmaceutico.
Another direct thrombin inhibitor, ximelagatran, did not show advantages over other anticoagulants and it was withdrawn from the market.
Ximelagatran (Exanta[R]) is a direct thrombin inhibitor that is taken orally in a fixed dose.
Liver function abnormalities, which caused the only previously available oral direct thrombin inhibitor, ximelagatran, to be denied FDA approval, were infrequent in both groups.